EARLY-STAGE CLINICAL INVESTMENT OPPORTUNITY
A New Approach to Menopause Care
Built on Proven Clinical Science
A non-estrogen, topical solution leveraging known physiological pathways, already being applied in real-world clinical settings and structured for scalable commercialization.
Access the Clinical & Commercial Deck
Review the mechanism of action, clinical validation, and our commercialization roadmap.
505(b)(2)
Regulatory Pathway
Built on 2
Approved Compounds
Active Real-World
Clinical Use
Ex-Pfizer
Commercial Leadership
De-Risking the Science. Built to Scale
Why investors are paying attention to this model now
Massive,
Underserved Market
Up to 47% of women experience menopause-related symptoms, yet treatment adoption remains low.
Clear Demand for
Non-Estrogen Solutions
Existing treatments are not suitable for many women because of contraindications or elevated risk factors, creating strong demand for safer alternatives.
Built on
Proven Compounds
Uses widely studied compounds with known safety and biological effects.
No Discovery Risk
By utilizing previously approved molecules, we bypass the years of high-failure-rate lab research typical of traditional biotech.
Active Clinical Application
Currently being utilized by patients in real-world clinical environments, validating efficacy early.
Structured for Efficient Scale
Leveraging a faster regulatory pathway with a model designed for efficient commercial scale.
A Structural Gap
in Standard of Care
Despite clear clinical awareness, this category remains underserved due to limitations in current treatment frameworks.
Hormone-Based Limitation
The standard of care relies heavily on estrogen-based therapies, which are not suitable for a large segment of patients.
Innovation Bottleneck
Traditional drug development requires long timelines, high capital, and carries significant failure risk, slowing progress in this category.
Mismatch Between Need and Adoption
While symptoms are widely recognized in clinical practice, treatment adoption remains low due to safety concerns and limited options.
Timing
Shift
Advances in formulation, combined with changing patient preferences, are creating a window for new, non-hormonal approaches to emerge.
A New Approach to Women’s Intimacy & Menopause Care
A non-estrogen, topical formulation built on validated compounds, structured for real-world clinical application and scalable commercialization.
JL-112 is a topical, non-estrogen formulation designed to address menopause-related symptoms by combining two widely studied compounds with established biological effects.
Rather than relying on new molecule discovery, this approach applies known physiological pathways in a simplified, targeted format.
Because these compounds are already well understood, the model reduces development complexity while creating a more efficient path to clinical adoption and scale.
Known mechanisms. Applied differently. Built to scale.
Already in Use. Already Validated.
Currently being applied in real-world clinical settings.
Active Clinical Use: Currently being applied with patients in clinical environments.
Established Safety Profile: Built on compounds with known safety and widespread use.
Observed Demand Signal: Early indication of demand within an underserved category.
Clear Path to Scale: Transitioning from clinical application to structured commercialization.
The Playbook to
Navigate Pharma
Executed by Those Who Wrote It
Medical plausibility requires structured commercial execution to realize investor returns.
Big Pharma Pedigree
Former Pfizer executive bringing over three decades of direct pharmaceutical growth and commercialization experience.
Regulatory Pattern Recognition
Deep, proven expertise in navigating complex FDA pathways, driving medical research to market-accepted outcomes.
Built for Commercial Scale
Leadership is structurally aligned to formalize this clinical model into a scalable commercial brand, positioning the asset for broad pharmaceutical distribution when ready.
Michael Rubin, CEO
The Timing is Now: Surging Demand Meets De-Risked Science
Rising demand, validated science, and a clear gap are converging at the same time.
Growing Market Attention
Global focus and capital are rapidly shifting toward women's health innovation.
Clear White Space
The gap between patient suffering and available treatments remains a measurable, multi-billion dollar void.
Validated Mechanics
Built on a physiological framework the medical and pharmaceutical communities already trust.
Strategic Entry
Access this opportunity during its crucial formalization phase, prior to major institutional funding.
Right market. Proven foundation. Timed for scale.
Clear Path to Market
Built to scale with the intention to commercialize through well-established pharma product distribution, when ready.
Built to become a scalable women’s health asset with long-term commercial value.
The company is being developed with a clear objective:
to translate early clinical use into a structured, scalable product positioned for well-established pharmaceutical distribution, when ready.
This category is ready: demand is growing, current care leaves room for improvement, and the team is focused, resourced, and experienced in both clinical application and commercialization through established pharmaceutical channels.
By combining validated science with a simplified, capital-efficient path, the company is positioned to move from early-stage development into a women’s health asset with a clear path toward broader commercial distribution.
From clinical use → commercial adoption → broader pharmaceutical distribution.
FAQ
Due Diligence Starts Here
What is JL-112?
A non-estrogen, topical formulation combining two widely studied compounds (Sildenafil and Oxytocin) into a single application.
How does this reduce biotech risk?
It uses previously approved compounds and follows the 505(b)(2) pathway—reducing time, cost, and early-stage failure risk.
Is this already being used?
Yes. The formulation is currently being applied in real-world clinical settings.
Why does this gap exist?
Current treatments are largely hormone-based, limiting adoption due to safety concerns and contraindications.
Why is non-estrogen important?
It expands access to patients who cannot or choose not to use hormone-based therapies.
What is the mechanism behind it?
It combines known pathways associated with blood flow and tissue response, using compounds already understood in medical practice.
Is the IP protected?
Yes. Patent applications have been filed, with ongoing efforts to strengthen global protection.
Why this team?
Led by a former Pfizer executive with 30+ years of experience in pharma commercialization and regulatory pathways.
What are the next steps?
Preparing for FDA engagement under the 505(b)(2) pathway following formulation and stability work.
How do investors make money?
The strategy is to scale JL-112 into a product opportunity positioned for broader pharmaceutical distribution and commercial growth, when ready.
Evaluate the Science.
Review the Economics.
See exactly how we are leveraging established clinical logic to capture a multi-billion dollar healthcare gap.
For accredited investors seeking a clinically grounded healthcare thesis.